Kazia Therapeutics Limited (NASDAQ: KZIA) has announced the appointment of Mr. Robert Apple (NASDAQ:AAPL) as a Non-Executive Director and Mr. Bryce Carmine as Chairman. These additions to the board aim to enhance oversight and stewardship as the company enters a growth phase. Mr. Apple brings over 25 years of experience in the pharmaceutical industry to his role, while Mr. Carmine brings valuable expertise from his previous positions at Eli Lilly & Co (NYSE:LLY). Kazia Therapeutics is focused on oncology drug development and is currently developing the lead drug paxalisib, which offers targeted treatment for brain cancer. The company anticipates final data from a pivotal study to be available in the first half of 2024. Kazia Therapeutics is also developing EVT801, a VEGFR3 inhibitor, for advanced solid tumors.
Kazia Therapeutics Adds Robert Apple to Board and Appoints Bryce Carmine as Chairman
Date:
Updated: [falahcoin_post_modified_date]
More like thisRelated
Revolutionary Small Business Exchange Network Connects Sellers and Buyers
Revolutionary SBEN connects small business sellers and buyers, transforming the way businesses are bought and sold in the U.S.
District 1 Commissioner Race Results Delayed by Recounts & Ballot Reviews, US
District 1 Commissioner Race in Orange County faces delays with recounts and ballot reviews. Find out who will come out on top in this close election.
Fed Minutes Hint at Potential Rate Cut in September amid Economic Uncertainty, US
Federal Reserve minutes suggest potential rate cut in September amid economic uncertainty. Find out more about the upcoming policy decisions.
Baltimore Orioles Host First-Ever ‘Faith Night’ with Players Sharing Testimonies, US
Experience the powerful testimonies of Baltimore Orioles players on their first-ever 'Faith Night.' Hear how their faith impacts their lives on and off the field.
